Meta-analysis Of The Treatment Of Hp In Efficacy And Safety Of Jinghuaweikang Combined With PPI Triple Therapy

ObjectiveCollection has been published with Jinghuaweikang with proton pump inhibitor(PPI)triple therapy in the treatment of helicobacter pylori correlation between chronic gastritis or peptic ulcer related case-control study Meta analysis.MethodsWe searched Cochrane Library,Medline,PubMed,EMBASE,ISI Web of Science,CNKI and Wan Fang database from January 1,2000 to November22,2017 to collect randomized controlled trials(RCTs)about JPTR for the treatment of H.pylori associated chronic gastritis or peptic ulcer.Two reviewers independently screened literatures according to the inclusion and exclusion criteria,extracted data and assessed the risk ofbias of included studies.Then meta-analysis was performed by using RevMan 5.0software.ResultsA total of 22 RCTs were included,including 3091 patients with Hp-positive chronic gastritis or peptic ulcer.Meta analysis showed that(1)JPTR vs.PPI triple therapy(PTR):JPTR in the H.pylori eradication rate,digestive tract symptoms were better than the control group,and the differences were statistically significant [ OR = 1.96,95% CI(1.47,2.60),P <0.001;OR = 1.75,95% CI(1.27,2.41),P <0.001];in the incidence of adverse reactions,JPTR adverse reaction rate was lower than the control group,but thedifference was not statistically significant [OR = 0.67,95% CI(0.36,1.25),P=0.21];(2)JPTR vs.bismuth-containing quadruple therapy(BCQT): JPTR was superior to BCQT in terms of H.pylori eradication rate and digestive tract symptom relief.But there was no significant difference between the two groups(OR =0.97,95%CI 0.75,1.26,P=0.83)OR= 1.37,95% CI(0.97,1.94),P>=0.07].In the incidence of adverse reactions,JPTR was lower than BCQT,with significant difference between the two groups [OR = 0.25,95%CI(0.15,0.44),P<0.001].ConclusionJPTR can improve the H.pylori eradication rate,promote digestive tract symptoms and reduce the adverse drug reactions.